Weight loss drugs that aim to radically curb appetites and prevent a host of obesity-related health problems are seeing unprecedented demand. At the same time, these drugs — sold under the brand names Ozempic, Wegovy and Zepbound — are raising questions for the food industry and companies that rely on cravings to sell their products. Capital Group portfolio manager Carl Kawaja shares his view on the heavy impact of weight loss drugs. #CapGroupGlobal
For full disclosures go to capitalgroup.com/global-disclosures
For our latest insights, practice management ideas and more, subscribe to Capital Ideas at getcapitalideas.com. If you’re based outside of the U.S., visit capitalgroup.com for Capital Group insights.
Watch our latest podcast, Conversations with Mike Gitlin, on YouTube: https://bit.ly/CG-Gitlin-playlist
This content is published by Capital Client Group, Inc.
U.K. investors can view a glossary of technical terms here: https://bit.ly/49rdcFq
To stay informed, follow us
LinkedIn: https://bit.ly/42uSYbm
YouTube: https://bit.ly/4dFTE1B
Follow Mike Gitlin: https://www.linkedin.com/in/mikegitlin/
About Capital Group
Capital Group was established in 1931 in Los Angeles, California, with the mission to improve people’s lives through successful investing. With our clients at the core of everything we do, we offer carefully researched products and services to help them achieve their financial goals.
Learn more: capitalgroup.com
Join us: capitalgroup.com/about-us/careers.html
Copyright ©2024 Capital Group
